WO2022146029A1 - Composition, pour soulager une maladie musculaire et augmenter la masse musculaire, comprenant des déchets de sésame - Google Patents

Composition, pour soulager une maladie musculaire et augmenter la masse musculaire, comprenant des déchets de sésame Download PDF

Info

Publication number
WO2022146029A1
WO2022146029A1 PCT/KR2021/020168 KR2021020168W WO2022146029A1 WO 2022146029 A1 WO2022146029 A1 WO 2022146029A1 KR 2021020168 W KR2021020168 W KR 2021020168W WO 2022146029 A1 WO2022146029 A1 WO 2022146029A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
sesame
muscle
sesame seed
group
Prior art date
Application number
PCT/KR2021/020168
Other languages
English (en)
Korean (ko)
Inventor
하태열
안지윤
정창화
서효덕
엄민영
유아영
Original Assignee
한국식품연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210190006A external-priority patent/KR20220095157A/ko
Application filed by 한국식품연구원 filed Critical 한국식품연구원
Publication of WO2022146029A1 publication Critical patent/WO2022146029A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Definitions

  • the present invention was made by the project specific number 1711123462 and detailed project number E0160500-05 under the support of the Ministry of Science and ICT. ) (Main Project Expenses)”, the research project title is “Research on improvement of muscle loss in the elderly using useful food ingredients”, the lead institution is the Korea Food Research Institute, and the research period is from January 1, 2020 to December 31, 2020.
  • the present invention relates to a composition for improving muscle disease and increasing muscle mass, including a sesame seed extract extract, and more particularly, to an improvement in muscle loss, an increase in muscle mass, and the effect of improving exercise performance due to the sesame seed extract extract.
  • the causes of sarcopenia include lack of hormones such as growth hormone and sex hormone, imbalance in the synthesis and degradation of muscle protein, inactivity, obesity, increase in inflammatory cytokines, decreased mitochondrial function, and insulin resistance. have. In particular, it is reported that obesity and visceral fat increase with increasing age, and sarcopenia is induced as inflammatory cytokines increase with this.
  • sesame seeds are an annual herb belonging to the genus Pedaliaceae . If you look at the nutritional components of sesame, it contains 51% lipid, 20% protein, and 15% carbohydrate. Compared to rice and wheat, it is rich in calcium, phosphorus, zinc, iron, vitamins B1, B2, and unsaturated fatty acids. In addition, sesame contains 0.1- and sesaminol 0.3- and sesamin, which exhibit antioxidant effects.
  • sesame meal which is an essential by-product, contains a large amount of ingredients effective for the human body.
  • the main active ingredients present in sesame seeds include lignan components such as sesamin, sesaminol, sesaminol, and pinoreisnol. They exist mainly in the form of water-soluble glycosides bound to glucose, and the content is about 1%.
  • lignan glycosides have an inhibitory effect on lipid peroxidation, and that the lipid peroxidation inhibitory effect increases depending on the concentration of the lignan glycoside.
  • lignan components of sesame seeds are known to prevent oxidation of low density lipoprotein (LDL).
  • LDL low density lipoprotein
  • sesaminol glucosides have been reported to have strong antioxidant and anti-atherosclerotic properties.
  • the present inventors confirmed that the sesame seed extract exhibits an inhibitory effect on muscle atrophy under the conditions of inducing muscle loss, and has an excellent degree of promoting differentiation from myoblasts to myotubes.
  • an object of the present invention is sarcopenia, muscular atrophy, muscle dystrophy, cardiac atrophy, atony, muscular dystrophy, muscle containing sesame seed extract It is to provide a food composition for improving at least one muscle disease selected from the group consisting of dystrophy, and myasthenia gravis.
  • Another object of the present invention is to provide a food composition for increasing muscle mass comprising a sesame seed extract.
  • Another object of the present invention is to provide a food composition for improving exercise performance comprising a sesame seed extract.
  • Another object of the present invention is to prevent at least one muscle disease selected from the group consisting of sarcopenia, muscular atrophy, muscular dystrophy, cardiac atrophy, dystonia, muscular dystrophy, muscular dystrophy, and myasthenia gravis, including sesame seed extract, or To provide a pharmaceutical composition for treatment.
  • Another object of the present invention is to improve, prevent or treat muscle diseases of the sesame seed extract; gain muscle mass; And it relates to the use of improving exercise performance.
  • the present invention relates to a composition for improving muscle disease and increasing muscle mass, comprising the sesame seed extract, and the ethanol fraction of the hot water extract from sesame seed according to the present invention has the effect of improving muscle loss, increasing muscle mass and improving exercise performance. indicates.
  • the present inventors confirmed that the ethanol fraction of hot water extract from sesame seeds exhibited an inhibitory effect on muscle atrophy under the condition of inducing muscle loss, and also increased the expression level of differentiation-related important proteins in the differentiation of myoblasts into myotubes.
  • One aspect of the present invention includes sesame seed extract for sarcopenia, muscular atrophy, muscle dystrophy, cardiac atrophy, atony, muscular dystrophy, muscle degeneration It is a food composition for improving at least one type of muscle disease selected from the group consisting of myasthenia gravis and myasthenia gravis.
  • the sesame seed extract may be extracted with one or more solvents selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical fluid and a supercritical fluid, preferably water, an aqueous methanol solution and It may be extracted with one or more solvents selected from the group consisting of an aqueous ethanol solution, for example, it may be a hot water extract obtained by extracting water as a solvent, but is not limited thereto.
  • the sesame seed extract hot water extract may be obtained as a water-soluble fraction after hot water extraction of defatted sesame seeds or centrifugation by dissolving dry powder of sesame seeds in water.
  • a sesame extract was prepared by pulverizing the sesame meal obtained after milking sesame, and then extracting it with hot water at 100° C. for 1 hour, followed by centrifugation to obtain a supernatant.
  • the sesame extract obtained by the above method contains sesaminol glycosides, and their content is 1 to 5% by weight, preferably 2 to 4% by weight, based on the total weight of the extract.
  • One aspect of the present invention relates to a method for preparing a sesame seed extract.
  • the sesame meal extract includes a solvent crude extract and a solvent fraction of sesame meal, as described above.
  • the manufacturing process of the sesame meal extract according to the present invention will be described in more detail as follows: It is extracted with an extraction solvent in an amount of about 10 to 50 times the weight of the sesame meal. After extraction, the filtrate is collected by filtration.
  • the extraction temperature is not particularly limited, but is preferably 15 to 110°C, preferably 20 to 100°C.
  • the extraction process can be repeated once or several times, and a method of re-extraction after the first extraction can be adopted. This is to prevent this because the extraction efficiency may be lowered only by the first extraction.
  • the filtered extract thus obtained may be prepared as a powdered sesame seed extract by freeze-drying to be suitable for use.
  • the extraction method used in the present invention may be any method commonly used, for example, cold extraction, hot water extraction, ultrasonic extraction, or reflux cooling extraction method, but is not limited thereto.
  • the sesame meal extract may be an alcohol fraction obtained by fractionating the sesame meal hot water extract with alcohol.
  • the ion exchange resin may be one selected from the group consisting of a cation exchange resin and an anion exchange resin. It may be more than one, but is not limited thereto.
  • the solvent is 10% to 100% (v/v), 20% to 100% (v/v), 30% to 100 % (v/v), 40% to 100% (v/v), 50% to 100% (v/v), 10% to 80% (v/v), 20% to 80% (v/v) , 30% to 80% (v / v), 40% to 80% (v / v) or 50% to 80% (v / v) of a linear or branched alcohol solution having 1 to 4 carbon atoms, for example, It may be an aqueous solution of 60% (v/v) straight-chain or branched alcohol having 1 to 4 carbon atoms, but is not limited thereto.
  • the alcohol aqueous solution may be at least one selected from the group consisting of methanol aqueous solution, ethanol aqueous solution, propanol aqueous solution, and butanol aqueous solution, for example, may be an ethanol aqueous solution, but is not limited thereto.
  • the alcohol fraction of the sesame meal hot water extract may be an ethanol fraction of the sesame meal hot water extract, and the ethanol fraction may contain sesaminol glycosides.
  • sesaminol glycoside refers to a form in which sesaminol is combined with glucose. Sesaminol glycosides are classified into sesaminol-1 glycosides (sesaminol monoglucoside), sesaminol-2 glycosides (sesaminol diglucoside) and sesaminol-3 glycosides (sesaminol triglucoside) according to the number of glucose bound to sesaminol.
  • the sesaminol glycoside according to the present invention can be isolated and purified from nature.
  • the sesaminol glycoside can be isolated and purified from sesame.
  • Sesame seeds contain lignan components such as sesaminol, sesaminol glycosides, sesamin and sesamolin. Since most of the above lignan components are water-soluble, in order to separate them, it is preferable to separate the oil-soluble component from the sesame and then separate the water-soluble material.
  • sesaminol glycosides were separated from the extract using a cation exchange resin after hot water extraction of the sesame meal obtained after milking sesame.
  • the method for isolating the sesaminol glycoside according to the present invention is not limited thereto, and any method capable of separating the sesaminol glycoside from sesame may be used.
  • sarcopenia may be obese sarcopenia or senescent sarcopenia.
  • the food composition of the present invention When used as a food additive, the food composition may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method.
  • foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, There are alcoholic beverages, vitamin complexes, and the like, and includes all foods in a conventional sense.
  • the beverage may contain various flavoring agents or natural carbohydrates as additional ingredients.
  • natural carbohydrates monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharin and aspartame may be used.
  • the ratio of the natural carbohydrate may be appropriately determined by the selection of those skilled in the art.
  • the food composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol , a carbonation agent used in carbonated beverages, and the like.
  • the food composition of the present invention may contain fruit for the production of natural fruit juice, fruit juice beverage, and vegetable beverage. These components may be used independently or in combination. The proportion of these additives may also be appropriately selected by those skilled in the art.
  • Another aspect of the present invention is a food composition for increasing muscle mass comprising a sesame seed extract.
  • the sesame seed extract may be extracted with one or more solvents selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical fluid and a supercritical fluid, for example, water as a solvent It may be an extracted hot water extract, but is not limited thereto.
  • the sesame meal extract may be an alcohol fraction obtained by fractionating the sesame meal hot water extract with alcohol.
  • the alcohol may be at least one selected from the group consisting of methanol, ethanol, propanol and butanol, for example, may be ethanol, but is not limited thereto.
  • the ion exchange resin may be one selected from the group consisting of a cation exchange resin and an anion exchange resin. It may be more than one, but is not limited thereto.
  • composition for increasing muscle mass is from the group consisting of transversus abdominis (TA), extensor Digitorum Longus (EDL), calf (Gastroc), soleus, quadriceps, and triceps (Triceps). It may be to increase one or more selected muscles, preferably to increase the quadriceps or triceps, but is not limited thereto.
  • Another aspect of the present invention is a food composition for improving exercise performance comprising a sesame seed extract.
  • the sesame seed extract may be extracted with one or more solvents selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical fluid and a supercritical fluid, for example, water as a solvent It may be an extracted hot water extract, but is not limited thereto.
  • the sesame meal extract may be an alcohol fraction obtained by fractionating the sesame meal hot water extract with alcohol.
  • the alcohol may be at least one selected from the group consisting of methanol, ethanol, propanol and butanol, for example, may be ethanol, but is not limited thereto.
  • the ion exchange resin may be one selected from the group consisting of a cation exchange resin and an anion exchange resin. It may be more than one, but is not limited thereto.
  • Another aspect of the present invention is sarcopenia, muscular atrophy, muscular dystrophy, cardiac atrophy, dystonia, muscular dystrophy, muscle dystrophy, and one or more muscle diseases selected from the group consisting of myasthenia gravis, including sesame seed extract, prevention or treatment It is a pharmaceutical composition for
  • the sesame seed extract may be extracted with one or more solvents selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical fluid and a supercritical fluid, for example, water as a solvent It may be an extracted hot water extract, but is not limited thereto.
  • the sesame meal extract may be an alcohol fraction obtained by fractionating the sesame meal hot water extract with alcohol.
  • the alcohol may be at least one selected from the group consisting of methanol, ethanol, propanol and butanol, for example, may be ethanol, but is not limited thereto.
  • the ion exchange resin may be one selected from the group consisting of a cation exchange resin and an anion exchange resin. It may be more than one, but is not limited thereto.
  • sarcopenia may be obese sarcopenia or senescent sarcopenia.
  • the pharmaceutical composition of the present invention may be used as a pharmaceutical composition comprising a pharmaceutically effective amount of a sesame seed extract and/or a pharmaceutically acceptable carrier.
  • the term "pharmaceutically effective amount” means an amount sufficient to achieve the efficacy or activity of the above-mentioned sesame seed extract.
  • Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are commonly used in formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
  • the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like, in addition to the above components.
  • the pharmaceutical composition according to the present invention may be administered to mammals including humans by various routes.
  • the administration method may be any method commonly used, for example, it may be administered by routes such as oral, skin, intravenous, intramuscular, subcutaneous, and the like.
  • a suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and response sensitivity of the patient, An ordinarily skilled physician can readily determine and prescribe a dosage effective for the desired treatment or prophylaxis.
  • the pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person of ordinary skill in the art to which the present invention pertains. Or it can be prepared by introducing into a multi-dose container.
  • the formulation may be in the form of a solution, suspension, or emulsion in oil or an aqueous medium, or may be in the form of an extract, powder, granule, tablet, capsule, or gel (eg, hydrogel), and may additionally include a dispersant or stabilizer. .
  • the present invention relates to a composition for improving muscle disease and increasing muscle mass comprising a sesame seed extract, wherein the sesame seed extract exhibits an effect on improving muscle loss, increasing muscle mass and improving exercise performance thereby, effectively treating muscle disease improvement, prevention or treatment; gain muscle mass; And it can be used to improve exercise performance.
  • SDG sesaminol diglucoside
  • SDG sesaminol diglucoside
  • STG sesaminol It is a graph showing the HPLC chromatogram result of triglucoside
  • Figure 2 is a western blotting showing the effect of the sesame seed ethanol fraction on protein expression in C2C12 myotubes treated with palmitic acid (PA) according to an embodiment of the present invention. This is the result picture.
  • PA palmitic acid
  • Figure 3a is a graph showing the mRNA expression level of MURF according to the treatment amount of the sesame seed ethanol fraction in C2C12 myotube cells treated with PA according to an embodiment of the present invention.
  • Figure 3b is a graph showing the mRNA expression level of Atrogin-1 according to the treatment amount of the sesame seed ethanol fraction in C2C12 myotube cells treated with PA according to an embodiment of the present invention.
  • Figure 4a is a fluorescence micrograph of myotube cells according to the treatment amount of each concentration of sesame seed ethanol fraction in C2C12 myotube cells treated with dexamethasone (DEX) according to an embodiment of the present invention.
  • Figure 4b is a graph showing the fusion index (fusion index) according to the treatment amount of each concentration of sesame seed ethanol fraction in C2C12 myotube cells treated with DEX according to an embodiment of the present invention.
  • FIG. 5 is a graph showing the mRNA expression level of Atrogin-1 according to the treatment amount by concentration of the sesame seed ethanol fraction in C2C12 myotube cells treated with DEX according to an embodiment of the present invention.
  • FIG. 6 is a western blotting result photograph showing the protein expression level according to the amount of treatment of the ethanol fraction from sesame seed during differentiation of C2C12 myotube cells according to an embodiment of the present invention.
  • 7A is a graph showing the mRNA expression levels of Total MHC and MHC2A according to the amount of ethanol fraction treated in C2C12 myotube cells according to an embodiment of the present invention.
  • FIG. 7B is a graph showing the mRNA expression levels of MyoD, MyoG, and Myf5 according to the amount of treatment of the sesame seed ethanol fraction upon differentiation of C2C12 myotube cells according to an embodiment of the present invention.
  • Figure 8a is a graph showing the change in body weight according to the sesame seed ethanol fraction addition diet for the aging muscle loss model prepared according to an embodiment of the present invention.
  • Figure 8b is a graph showing the change in muscle weight according to the sesame seed ethanol fraction addition diet for the aging muscle loss model prepared according to an embodiment of the present invention.
  • Figure 9a is a graph showing the change in grip strength (Grip strength) according to the sesame seed ethanol fraction addition diet for the aging muscle reduction model prepared according to an embodiment of the present invention.
  • Figure 9b is a graph showing the change in total running time (Total running time) according to the sesame seed ethanol fraction addition diet for the aging muscle loss model prepared according to an embodiment of the present invention.
  • Figure 10a is a graph showing the change in the mRNA expression level of the muscle atrophy marker gene MuRF1 according to the sesame seed ethanol fraction addition diet for the aging muscle loss model prepared according to an embodiment of the present invention.
  • sesame seeds were purchased from the market, selected, washed, dried, roasted, and then milked. After preparing sesame oil, the obtained sesame meal was powdered to pass through 40 mesh, stored in a -20°C freezer, and used as a sample.
  • Hot water was added to the sesame meal, followed by hot water extraction at 100° C. for 1 hour, and then the extract was filtered with three layers of gauze and centrifuged at 6,000 rpm for 30 minutes (Dupont Sorvall RC-5C, SORVALL, USA) to obtain a supernatant, The supernatant was filtered again with Whatman filter paper (Whatman filter paper NO. 2).
  • the measurement result shows that the hot water extract and the separated It was confirmed that the ethanol fraction contained sesaminol-2 glycosides (sesaminol diglucoside) and sesaminol-3 glycosides (sesaminol triglucoside).
  • Example 2 Inhibitory effect of palmitic acid-induced muscle atrophy by sesame seed extract
  • Mouse C2C12 myoblasts (Mouse C2C12 myoblast, CRL1772, American type cell collection (ATCC), USA) were maintained with DMEM (Dulbecco's Modified Eagle's Medium) supplemented with 10% Fetal bovine serum (FBS). After reaching 95%-confluence in a 6-well plate, the medium was replaced with DMEM medium containing 2% horse serum every 2 days. It was cultured for 4 days and differentiated into myotube cells.
  • DMEM Dulbecco's Modified Eagle's Medium
  • FBS Fetal bovine serum
  • the obtained cells were fixed with 4% formaldehyde at room temperature for 15 minutes, then permeablized with a 0.05% saponin solution for 30 minutes at room temperature, and then with 1% BSA solution. Blocked for 30 minutes. After reacting with the primary antibody (Total MHC) at 4°C overnight (overnight) conditions, washing with PBS, reacting the secondary fluorescent antibody at room temperature for 30 minutes, staining the nucleus with DAPI for 1 minute, and then using a fluorescence microscope The morphology of myotube cells was observed, and the fusion index was derived as an index indicating the degree of cell differentiation by expressing the number of nuclei in the root canal from the total nucleus as a percentage.
  • Example 2-1 On the fourth day of differentiation of C2C12 myotube cells prepared according to Example 2-1, 1.0, 2.5 or 5.0 ug/ml of sesame seed ethanol fraction (SG) was treated for 24 hours and cultured. Western blotting was performed in the same manner as in Example 2-2, but primary antibodies were used as MHC, MHC2A, MyoD, MyoG, and Myf5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition, pour soulager une maladie musculaire et augmenter la masse musculaire, comprenant des déchets de sésame. Une fraction d'éthanol d'un extrait de déchets de sésame à l'eau chaude présente des effets comprenant le soulagement de sarcopénie, une masse musculaire accrue et une capacité motrice améliorée due à celle-ci, et peut ainsi être efficacement utilisée pour soulager, prévenir ou traiter une maladie musculaire, augmenter la masse musculaire et améliorer une capacité motrice.
PCT/KR2021/020168 2020-12-29 2021-12-29 Composition, pour soulager une maladie musculaire et augmenter la masse musculaire, comprenant des déchets de sésame WO2022146029A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2020-0186797 2020-12-29
KR20200186797 2020-12-29
KR10-2021-0190006 2021-12-28
KR1020210190006A KR20220095157A (ko) 2020-12-29 2021-12-28 참깨박 추출물을 포함하는 근육 질환 개선 및 근육량 증대용 조성물

Publications (1)

Publication Number Publication Date
WO2022146029A1 true WO2022146029A1 (fr) 2022-07-07

Family

ID=82260725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/020168 WO2022146029A1 (fr) 2020-12-29 2021-12-29 Composition, pour soulager une maladie musculaire et augmenter la masse musculaire, comprenant des déchets de sésame

Country Status (1)

Country Link
WO (1) WO2022146029A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115088840A (zh) * 2022-07-13 2022-09-23 江苏经贸职业技术学院 一种利用食品加工副产物开发的全营养食品及制作工艺

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1095795A (ja) * 1996-09-19 1998-04-14 Takemoto Oil & Fat Co Ltd セサミノールトリグルコシドの分離方法
JP2014138581A (ja) * 2012-12-19 2014-07-31 Kao Corp ペットフード
CN106072573A (zh) * 2016-07-05 2016-11-09 郑州和正生物科技有限公司 一种适用于老年肌肉衰减症食用的特膳食品
WO2018079719A1 (fr) * 2016-10-27 2018-05-03 サントリーホールディングス株式会社 COMPOSITION POUR ACTIVATION DE ＰＧＣ－１α

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1095795A (ja) * 1996-09-19 1998-04-14 Takemoto Oil & Fat Co Ltd セサミノールトリグルコシドの分離方法
JP2014138581A (ja) * 2012-12-19 2014-07-31 Kao Corp ペットフード
CN106072573A (zh) * 2016-07-05 2016-11-09 郑州和正生物科技有限公司 一种适用于老年肌肉衰减症食用的特膳食品
WO2018079719A1 (fr) * 2016-10-27 2018-05-03 サントリーホールディングス株式会社 COMPOSITION POUR ACTIVATION DE ＰＧＣ－１α

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HSU DUR-ZONG, CHU PEI-YI, JOU I-MING: "Enteral sesame oil therapeutically relieves disease severity in rat experimental osteoarthritis", FOOD & NUTRITION RESEARCH, vol. 60, no. 1, 1 January 2016 (2016-01-01), pages 29807, XP055948726, ISSN: 1654-6628, DOI: 10.3402/fnr.v60.29807 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115088840A (zh) * 2022-07-13 2022-09-23 江苏经贸职业技术学院 一种利用食品加工副产物开发的全营养食品及制作工艺

Similar Documents

Publication Publication Date Title
US20100105766A1 (en) Composition for inhibition or prevention of bone density reduction
KR101457570B1 (ko) 올레아놀린산 아세테이트를 유효성분으로 포함하는 대사성 질환 예방 또는 치료용 약학적 조성물
EP2436388B1 (fr) Composition pour accroître de la biodisponibilité de la saponine
WO2014058142A1 (fr) Composition pharmaceutique contenant un extrait d'aster glehni en tant que principe actif pour la prévention et le traitement de l'obésité et de troubles métaboliques
WO2022146029A1 (fr) Composition, pour soulager une maladie musculaire et augmenter la masse musculaire, comprenant des déchets de sésame
KR101785495B1 (ko) 감국 추출물 또는 분획물을 유효성분으로 포함하는 비만, 비만 관련 질환 또는 합병증의 예방, 개선 또는 치료용 조성물
WO2017183902A1 (fr) Composition contenant des extraits de artemisia capillaris, sanguisorba officinalis et curcuma longa et un agent antiviral, en tant que principes actifs, destinée à prévenir ou traiter une maladie du foie
WO2016190566A9 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
WO2019050123A1 (fr) Composition alimentaire pour traiter l'obésité ou l'hyperlipidémie comprenant un extrait de fruit de terminalia chebula et un extrait de phyllanthus emblica
KR102519649B1 (ko) 캠퍼롤 및 에피카테킨 갈레이드를 포함하는 홍경천 추출물을 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물
WO2020218727A9 (fr) Peptide isolé dans un hydrolysat de protéines du ver de farine tenebrio molitor et composition le comprenant en tant que principe actif pour prévenir ou traiter une atteinte hépatique
KR20160123130A (ko) 감국 추출물 또는 분획물을 유효성분으로 포함하는 비만, 비만 관련 질환 또는 합병증의 예방, 개선 또는 치료용 조성물
WO2023003204A1 (fr) Composition anti-obésité contenant un extrait de rosa davurica en tant que principe actif
WO2022186414A1 (fr) Composition anti-inflammatoire comprenant des extraits d'epimendium koreanum nakai, de polygala tenuifolia wild, et de polyporus umbellatus fries ou un mélange de ces derniers en tant que principe actif
WO2018038313A1 (fr) Nouveau composé d'acide diynoique, et composition pharmaceutique pour prévenir ou traiter des maladies osseuses le comprenant
WO2016204493A1 (fr) Nouveau composé (ks 513) isolé de pseudolysimachion rotundum var. subintegrum, la composition le comprenant comme ingrédient actif pour la prévention ou le traitement de l'allergie, d'une maladie inflammatoire, de l'asthme ou d'une maladie pulmonaire obstructive chronique et son utilisation
WO2016137085A1 (fr) Composition alimentaire pour favoriser la croissance osseuse et augmenter la densité osseuse, contenant un extrait de graine de carthame, un extrait de boswellia et un extrait de scutellaria baicalensis comme principes actifs
WO2020122373A1 (fr) Composition comprenant un extrait de glycyrrhiza uralensis en tant que principe actif pour la prévention, l'atténuation ou le traitement du syndrome d'hypogonadisme d'apparition tardive
KR20220095157A (ko) 참깨박 추출물을 포함하는 근육 질환 개선 및 근육량 증대용 조성물
JP2001187732A (ja) レプチン分泌促進剤
JP2022535353A (ja) インディアングーズベリー抽出物と大麦若葉抽出物との複合物（ｉｂ複合物）を有効成分として含む肥満及び／または糖尿を伴うメタボリックシンドロームの予防、改善治療用組成物
KR100551718B1 (ko) 지방산 합성효소의 활성을 억제할 수 있는 비만 억제용조성물
WO2023048504A1 (fr) Composition pour prévenir ou traiter des maladies associées à une faiblesse musculaire ou une sarcopénie, contenant un extrait de rosa davurica pallas en tant que principe actif
WO2017213437A1 (fr) Composition comprenant un extrait de sicyos angulatus ou une fraction de ce dernier en tant qu'ingrédient efficace dans la prévention ou le traitement d'une maladie métabolique
WO2024172325A1 (fr) Composition contenant un extrait de ponciri fructus pour prévenir ou traiter une maladie musculaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21915827

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21915827

Country of ref document: EP

Kind code of ref document: A1